Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
Global Haemophilia Treatment Market: By Disease Type: Haemophilia A, Haemophilia B, Von Willebrand Disease, Others; By Product Type; By Therapy; By End Use; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics; Competitive Landscape; Industry Events and Developments
Global Haemophilia Treatment Market Outlook
The global haemophilia treatment market is projected to grow at a CAGR of 5% between 2021 and 2026.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Advancements in Technology in Health Care Industry to Propel the Market Growth
The global haemophilia treatment industry is growing due to the increasing prevalence of bleeding disorders and their increasing severity, which has led to the advancement of medical expertise and the increasing amount of clinical research activities in haemophilia. In addition, owing to certain factors, such as the growing use of haemophilia prophylactic medication, the discovery of novel coagulating factors, scientific innovations, the booming biotechnology industry, increasing people's understanding, and increasing research and development focused on finding curative agents, the global demand for haemophilia treatment is thriving. Region-wise, North America led the industry in recent years and contributed a significant market share. Some of the drivers of regional development are expected to be the increasing prevalence of the disease and the propensity towards prophylaxis therapy. In the United States, at a very early age, people are afflicted with this condition.
Haemophilia Treatment: Market Segmentation
Haemophilia is a hereditary genetic disease that impairs the capacity of the body to regulate coagulation or blood clotting. In this disorder, bleeding from a damaged artery is poorly regulated by clotting factors; thus, coagulation does not occur.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By disease type, the market is divided into:
- Haemophilia A
- Haemophilia B
- Von Willebrand Disease
- Others
Based on product type, the market segmented into:
- Recombinant Factor Concentrate
- Plasma-derived Factor Concentrate
- Desmopressin
- Antifibrinolytics
- Others
Based on therapy, the market segmented into:
- Replacement Therapy
- Gene Therapy
- Immune Tolerance Induction Therapy
- Others
Based on end-use, the market segmented into:
- Hospital Pharmacy
- Retail Pharmacy
- Online
- Others
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Government Initiatives to Augment the Industry Growth of Haemophilia Treatment
The rise in several government policies would increase the industry's growth over the forecast period. Organizations such as the World Haemophilia Organization and governments in several countries perform education and diagnostic services. Government efforts to improve public health and treat vulnerable patients will fuel the market growth for haemophilia treatment in the near term. However, one of the main factors impeding progress would be the high cost of haemophilia medications. High investment, R&D, drug manufacturing and sales by manufacturers are factors resulting in the high cost of the drugs. For families in the middle- and lower-income classes, high retail prices are unaffordable, thereby restricting business growth.
Key Industry Players in the Global Haemophilia Treatment Market
The report gives a detailed analysis of the following key players in the global haemophilia treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Grifols SA
- F. Hoffmann-La Roche Ltd
- Pfizer, Inc.
- Baxter International, Inc.
- Bayer AG
- SANOFI
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2020 |
| Historical Period | 2017-2021 |
| Forecast Period | 2022-2027 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Disease Type, Product Type, Therapy, End Use, Region |
| Breakup by Disease Type | Haemophilia A, Haemophilia B, Von Willebrand Disease, Others |
| Breakup by Product Type | Recombinant Factor Concentrate, Plasma-derived Factor Concentrate, Desmopressin, Antifibrinolytics, Others |
| Breakup by Therapy | Replacement Therapy, Gene Therapy, Immune Tolerance Induction Therapy, Others |
| Breakup by End Use | Hospital Pharmacy, Retail Pharmacy, Online, Others |
| Breakup by Region | North America, Latin America, Europe, Middle East and Africa, Asia Pacific |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Grifols SA, F. Hoffmann-La Roche Ltd, Pfizer, Inc., Baxter International, Inc., Bayer AG, SANOFI, Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Haemophilia Treatment Market Analysis
8.1 Key Industry Highlights
8.2 Global Haemophilia Treatment Historical Market (2017-2021)
8.3 Global Haemophilia Treatment Market Forecast (2022-2027)
8.4 Global Haemophilia Treatment Market by Disease Type
8.4.1 Haemophilia A
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2017-2021)
8.4.1.3 Forecast Trend (2022-2027)
8.4.2 Haemophilia B
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2017-2021)
8.4.2.3 Forecast Trend (2022-2027)
8.4.3 Von Willebrand Disease
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2017-2021)
8.4.3.3 Forecast Trend (2022-2027)
8.4.4 Others
8.5 Global Haemophilia Treatment Market by Product Type
8.5.1 Recombinant Factor Concentrate
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2017-2021)
8.5.1.3 Forecast Trend (2022-2027)
8.5.2 Plasma-derived Factor Concentrate
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2017-2021)
8.5.2.3 Forecast Trend (2022-2027)
8.5.3 Desmopressin
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2017-2021)
8.5.3.3 Forecast Trend (2022-2027)
8.5.4 Antifibrinolytics
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2017-2021)
8.5.4.3 Forecast Trend (2022-2027)
8.5.5 Others
8.6 Global Haemophilia Treatment Market by Therapy
8.6.1 Replacement Therapy
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2017-2021)
8.6.1.3 Forecast Trend (2022-2027)
8.6.2 Gene Therapy
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2017-2021)
8.6.2.3 Forecast Trend (2022-2027)
8.6.3 Immune Tolerance Induction Therapy
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2017-2021)
8.6.3.3 Forecast Trend (2022-2027)
8.6.4 Others
8.7 Global Haemophilia Treatment Market by End Use
8.7.1 Hospital Pharmacy
8.7.1.1 Market Share
8.7.1.2 Historical Trend (2017-2021)
8.7.1.3 Forecast Trend (2022-2027)
8.7.2 Retail Pharmacy
8.7.2.1 Market Share
8.7.2.2 Historical Trend (2017-2021)
8.7.2.3 Forecast Trend (2022-2027)
8.7.3 Online
8.7.3.1 Market Share
8.7.3.2 Historical Trend (2017-2021)
8.7.3.3 Forecast Trend (2022-2027)
8.7.4 Others
8.8 Global Haemophilia Treatment Market by Region
8.8.1 Market Share
8.8.1.1 North America
8.8.1.2 Europe
8.8.1.3 Asia Pacific
8.8.1.4 Latin America
8.8.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 Grifols SA
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 F. Hoffmann-La Roche Ltd
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 Pfizer, Inc.
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 Baxter International, Inc.
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 Bayer AG
12.2.5.1 Company Overview
12.2.5.2 Product Portfolio
12.2.5.3 Demographic Reach and Achievements
12.2.5.4 Certifications
12.2.6 SANOFI
12.2.6.1 Company Overview
12.2.6.2 Product Portfolio
12.2.6.3 Demographic Reach and Achievements
12.2.6.4 Certifications
12.2.7 Others
13 Industry Events and Developments
List of Key Figures and Tables
1. Global Haemophilia Treatment Market: Key Industry Highlights, 2016 and 2026
2. Global Haemophilia Treatment Historical Market: Breakup by Disease Type (USD Billion), 2017-2021
3. Global Haemophilia Treatment Market Forecast: Breakup by Disease Type (USD Billion), 2022-2027
4. Global Haemophilia Treatment Historical Market: Breakup by Product Type (USD Billion), 2017-2021
5. Global Haemophilia Treatment Market Forecast: Breakup by Product Type (USD Billion), 2022-2027
6. Global Haemophilia Treatment Historical Market: Breakup by Therapy (USD Billion), 2017-2021
7. Global Haemophilia Treatment Market Forecast: Breakup by Therapy (USD Billion), 2022-2027
8. Global Haemophilia Treatment Historical Market: Breakup by End Use (USD Billion), 2017-2021
9. Global Haemophilia Treatment Market Forecast: Breakup by End Use (USD Billion), 2022-2027
10. Global Haemophilia Treatment Historical Market: Breakup by Region (USD Billion), 2017-2021
11. Global Haemophilia Treatment Market Forecast: Breakup by Region (USD Billion), 2022-2027
12. North America Haemophilia Treatment Historical Market: Breakup by Country (USD Billion), 2017-2021
13. North America Haemophilia Treatment Market Forecast: Breakup by Country (USD Billion), 2022-2027
14. Europe Haemophilia Treatment Historical Market: Breakup by Country (USD Billion), 2017-2021
15. Europe Haemophilia Treatment Market Forecast: Breakup by Country (USD Billion), 2022-2027
16. Asia Pacific Haemophilia Treatment Historical Market: Breakup by Country (USD Billion), 2017-2021
17. Asia Pacific Haemophilia Treatment Market Forecast: Breakup by Country (USD Billion), 2022-2027
18. Latin America Haemophilia Treatment Historical Market: Breakup by Country (USD Billion), 2017-2021
19. Latin America Haemophilia Treatment Market Forecast: Breakup by Country (USD Billion), 2022-2027
20. Middle East and Africa Haemophilia Treatment Historical Market: Breakup by Country (USD Billion), 2017-2021
21. Middle East and Africa Haemophilia Treatment Market Forecast: Breakup by Country (USD Billion), 2022-2027
22. Global Haemophilia Treatment Market Structure
Key Questions Answered in the Report
The global haemophilia treatment market is projected to grow at a CAGR of 5% between 2021 and 2026.
The industry is primarily driven by the increasing prevalence of bleeding disorders and their severity, increased use of haemophilia prophylactic medication, the discovery of novel coagulating factors, scientific innovations, booming biotechnology industry, widespread public awareness, and enhanced research and development.
The key trends augmenting the market’s growth are the rise in several government policies and increasing investments.
The major regions in the industry are North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific with North America accounting for the largest share in the market.
By disease type, the market is divided into Haemophilia A, Haemophilia B, and Von Willebrand disease, among others.
Based on product type, the market is segmented into recombinant factor concentrate, plasma-derived factor concentrates, desmopressin, and antifibrinolytics, among others.
Based on therapy, the market is segmented into replacement therapy, gene therapy, and immune tolerance induction therapy, among others.
The end-uses are hospital pharmacy, retail pharmacy, and online, among others.
The major players in the industry are Grifols SA, F. Hoffmann-La Roche Ltd, Pfizer, Inc., Baxter International, Inc., Bayer AG, and SANOFI, among others.
Analyst Review
The global haemophilia treatment market is being driven by the increasing prevalence of bleeding disorders and their severity in the historical period. Aided by the rise in several government policies and booming biotechnology industry, the market is expected to witness a further growth in the forecast period of 2021-2026, growing at a CAGR of 5%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its disease types, the global haemophilia treatment industry can be segmented into Haemophilia A, Haemophilia B, and Von Willebrand Disease, among others. Based on the product types, the industry can be classified into recombinant factor concentrate, plasma-derived factor concentrates, desmopressin, and antifibrinolytics, among others. By therapy, the various segments are replacement therapy, gene therapy, and immune tolerance induction therapy, among others. On the basis of end-use, hospital pharmacy, retail pharmacy, and online, others are the various categories. The major regional markets for haemophilia treatment are North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific, with North America accounting for the largest share of the market. The key players in the above market include Grifols SA, F. Hoffmann-La Roche Ltd, Pfizer, Inc., Baxter International, Inc., Bayer AG, and SANOFI, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER